<DOC>
	<DOCNO>NCT02914626</DOCNO>
	<brief_summary>Neovascular glaucoma potentially blinding condition characterize growth newvessels anterior part eye . This growth drive overexpression protein call Vascular Endothelial Growth Factor ( VEGF ) . That happen diseases diabetic retinopathy venous retinal occlusion , lead fast increase intraocular pressure ( IOP ) . Traditional treatment include laser photocoagulation retina order decrease VEGF formation . The investigator postulate use anti-VEGF intravitreal injection may accelerate recovery decrease need surgery case neovascular glaucoma .</brief_summary>
	<brief_title>Intravitreal Ranibizumab ( Lucentis® ) Neovascular Glaucoma- Randomized Controlled Study</brief_title>
	<detailed_description>This prospective , randomize control study aim evaluate efficacy ranibizumab ( Lucentis® ) adjunct treatment patient neovascular glaucoma . 28 patient neovascular glaucoma ( 14 study group 14 control standard care group ) recruit single center- University Sao Paulo Medical School General Hospital . A complete ophthalmologic exam carry , include obtention inform consent eligible patient willing participate study . Patients randomly assign either standard care- retinal laser photocoagulation clinical management intraocular pressure drop , standard care plus intravitreal ranibizumab injection . Two injection perform 30 day apart . The patient follow 6 month .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>IOP great 24 mmHg Iris anterior chamber neovascularization At least 120 degree open anterior chamber angle Visual acuity worse count finger fellow eye No light perception treat eye Any ocular infectious disease Use systemic steroid Lack medium transparency preclude laser photocoagulation Thromboembolic disease Known hypersensitivity ranibizumab Female participant childbearing age use oral contraceptive Use intravitreal antiVEGF last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Glaucoma , Neovascular</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Intraocular pressure</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>intravitreal injection</keyword>
</DOC>